Originally Posted by Iarons

As many of you are aware, over the past couple of years, I’ve been tracking and reporting on the companies and institutions involved in research and clinical trials using both stem cells and gene therapy in ophthalmology. With the help of several industry sources, I have been able to put together the most comprehensive list of who is involved and what they are doing.

Because I have been updating this information almost on a daily basis, I’ve decided to no longer post the information on my online Journal (Irv Arons’ Journal), as it is out-of-date almost as soon as I post it. Therefore, I will only offer my tables of information to those who are interested in receiving them, and put notices on these forums when there is substantial new information to report.

Here is what is currently available:

Stem Cells

Stem Cell Companies (and Institutions) Active in Ophthalmology (Version 6, Jan. 27, 2012)

A list of seventeen companies and institutions working with stem cells for ophthalmic applications. The table lists collaborators, the cell type being used, and the applications against which the cells will be applied.

Stem Cell Therapy in Ophthalmology by Applications (Version 2, Jan. 20, 2012)

A list of seven ophthalmic applications being tested in clinical trials. The table includes which companies/institutions are involved, the clinical trial status, and the clinical trial number for those which are currently active. (Nine active clinical trials are listed, with live links.)


Gene Therapy

Gene Therapy Companies/Institutions Active in Ophthalmology (Version 10, Jan. 27, 2012)

The table lists more than twenty-five companies and institutions actively pursuing gene therapy solutions to ophthalmic diseases. The table shows the delivery viral platform, the gene type being used (where known), the application, and clinical status.

Gene Therapy in Ophthalmology by Application (Version 2, Jan.11, 2012)

This table, like the one for stem cells, lists the ophthalmic indication, the company/institutions involved, the clinical status, and the clinical trial number. (Fourteen active clinical trials are listed, with live links.)

Anyone interested in receiving a copy of any or all of the above tables, please contact me via email (iarons(at)erols.com) and let me know which ones, or all four, that you wish to obtain. The tables are in pdf format, and as mentioned, contain live links to all of the clinical trials listed.

(I will be out of the country, on vacation, for the next two weeks, so I apologize in advance if delivery of the tables is slow.)

Irv Arons